Protective effects of S-methylisothiourea sulfate on different aspiration materials-induced lung injury in rats.
OBJECTIVE
The aim of this study was to evaluate the efficiency of inducible nitric oxide synthase (iNOS) specific inhibitor, S-methylisothiourea sulfate (SMT) in preventing lung injury after different pulmonary aspiration materials in rats.


METHODS
The experiments were performed in 80 Sprague-Dawley rats, ranging in weight from 220 to 250 g, randomly allotted into one of the eight groups (n=10): normal saline (NS, control), Biosorb Energy Plus (BIO), sucralfate (SUC), hydrochloric acid (HCl), NS+SMT treated, BIO+SMT treated, SUC+SMT treated, and HCl+SMT treated. NS, BIO, SUC, HCl were injected in to the lungs in a volume of 2 ml/kg. The rats received twice daily intraperitoneal injections of 20 mg(kg day) SMT (Sigma Chemical Co.) for 7 days. Seven days later, rats were killed, and both lungs in all groups were examined immunohistochemically and histopathologically.


RESULTS
Our data show that SMT inhibits the inflammatory response significantly reducing (p<0.05) peribronchial inflammatory cell infiltration, alveolar septal infiltration, alveolar edema, alveolar exudate, alveolar histiocytes, interstitial fibrosis, granuloma, and necrosis formation in different pulmonary aspiration models. Furthermore, our data suggest that there is a significant reduction in the activity of iNOS and arise in the expression of surfactant protein D in lung tissue of different pulmonary aspiration models with SMT therapy.


CONCLUSIONS
It was concluded that SMT treatment might be beneficial in lung injury, therefore shows potential for clinical use.
Guzel
Ahmet
A
Trakya University Faculty of Medicine, Department of Pediatrics, 22030 Edirne, Turkey. ahmetgzl@yahoo.com
Basaran
Umit Nusret
UN
Aksu
Burhan
B
Kanter
Mehmet
M
Yalcin
Omer
O
Aktas
Cevat
C
Guzel
Aygul
A
Karasalihoglu
Serap
S
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D007550:Isothiuronium / Q000008:administration & dosage / Q000031:analogs & derivatives*; D055370:Lung Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D011015:Pneumonia, Aspiration / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; D007550:Isothiuronium; D052247:Nitric Oxide Synthase Type II; C027744:S-methylisothiopseudouronium